Immunosuppression is frequently observed in the TME, primarily attributed to the lack of tumor-specific antigens and the activation of immune-suppressive signaling pathways, such as PD-1/PD-L1 and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)48. This evidence concerns the gene PDCD1 and neoplasm.